Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Common Equity (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Common Equity for 4 consecutive years, with $441.2 million as the latest value for Q4 2025.

  • For Q4 2025, Common Equity fell 12.25% year-over-year to $441.2 million; the TTM value through Dec 2025 reached $441.2 million, down 12.25%, while the annual FY2025 figure was $441.2 million, 12.25% down from the prior year.
  • Common Equity was $441.2 million for Q4 2025 at Day One Biopharmaceuticals, down from $450.9 million in the prior quarter.
  • The five-year high for Common Equity was $555.5 million in Q3 2024, with the low at $259.6 million in Q1 2022.
  • Historically, Common Equity has averaged $393.9 million across 4 years, with a median of $390.1 million in 2022.
  • The largest annual shift saw Common Equity decreased 28.01% in 2024 before it skyrocketed 61.56% in 2025.
  • Over 4 years, Common Equity stood at $332.0 million in 2022, then increased by 4.37% to $346.5 million in 2023, then skyrocketed by 45.08% to $502.8 million in 2024, then decreased by 12.25% to $441.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were $441.2 million in Q4 2025, $450.9 million in Q3 2025, and $460.8 million in Q2 2025.